Interestingly, this phenomenon was independent of PTEN and p-Akt status, indicating that there exists a group of GBM tumors in which the EGFR/PI3K/mTOR pathway is active by increased expression of some components, such as EGFR and PI3K p110α. This evidence concerns the gene EGFR and glioblastoma.